News & Articles

Dr. Michael Kiebish of BPGbio shares insight into its AI-powered NAi Interrogative Biology Platform and discusses the growing importance of multiomic data

In research conducted in mice, scientists identified a trio of existing medicines as promising candidates for treating a rare and severe form of infant leukemia caused by a genetic changed called KMT2A::AFF1

Drug Discovery USA 2026 to focus on emerging multifunctional small molecule and biologic approaches to drug difficult targets

Collaboration aims to discover and develop antibodies against multiple therapeutic targets designated by Merck

The U.S. FDA has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-molecule FGFR2/3 inhibitor, for the treatment of children with achondroplasia (ACH)

Dr. Becky Upton, President of Pistoia Alliance, looks to the future of lab innovation in this guest editorial

The treatment preserved quality of life

Co-occurrence of myocarditis with myositis and myasthenia gravis may also increase risk of death

Data presented at the AACR 2026 revealed a 44% reduction and growing urban concentration of U.S. phase I NSCLC trial sites between 2020 and 2024

Hear how the Program of Glyco-Immunology and Oncology (PGIO) is deciphering cancer’s ‘glyco code’ to pave the way for more precise diagnostics and next generation immunotherapies.

All patients were negative for minimal residual disease, and no patients experienced progression to active multiple myeloma during the median 15.3 months of follow-up

The investigational drug led to objective response and disease control in patients with late-stage disease

Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose disease progressed on prior KRAS G12C inhibitors

An updated trial analysis presented at AACR 2026 showed that the investigational KRAS G12D inhibitor zoldonrasib demonstrated clinical activity with a favorable safety profile in previously treated KRAS G12D‑mutant NSCLC patients

Extended immunotherapy showed manageable long‑term safety in adolescents and young adults with alveolar soft part sarcoma, according to phase II data presented at AACR 2026

Expanded antibody portfolio enhances detection of biologics and YTE-modified therapeutics for bioanalytical applications

Why software integration is the key to reproducible, data-driven biologics workflows

Povair Sciences addresses critical bottlenecks in mAb development with innovative filtration solutions

Signals BioDesign is a cloud-native molecular cloning solution that enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing

SPINRAZA is an antisense oligonucleotide therapy that increases production of survival motor neuron (SMN) protein, essential for motor neuron function

The technology selectively shuts down cancer reproducing cells

Boehringer Ingelheim expands its collaboration with OpenProtein.AI following successful initial deployment, co-developing integrated workflows for next-generation therapeutic development

Strategic collaboration integrates organ-on-chip technology into preclinical glioblastoma research to improve translational relevance

Forge Editing is a technique which uses no CRISPR proteins, but still benefits from the reprogrammability allowed by an RNA targeting region

New imaging model in the PerkinElmer Spotlight Aurora family, the Aurora-I, brings powerful smart adaptive IR imaging capabilities to FTIR microscopy analysis